Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 31;14:1229558. doi: 10.3389/fimmu.2023.1229558

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Greve, Beishuizen, Hagleitner, Loeffen, Veening, Boes, Peperzak, Diez and Meyer-Wentrup

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Treatment with nivolumab + BV +/- bendamustine. Flowchart of included patients and their treatment. Five patients had CMR after 4 cycles of N-BV treatment and were consolidated with HD-BEAM (n = 3) or RT (n = 2). Those with PMR continued with 2 cycles of bendamustine + BV, leading to CMR in 4 more patients, consolidated with HD-BEAM (n = 1), RT (n = 1) or HD-BEAM + RT (n = 2). The last patient was treated with a single cycle of DHAP + BV, leading to CMR, and had consolidation therapy with HD-BEAM + RT.